Prometheus’ Lotronex REMS Could Lose Its Sticker Verification Requirement
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seeks advisory committee input on options for revising the irritable bowel syndrome drug’s Risk Evaluation and Mitigation Strategy, including eliminating a requirement for paper-based prescriptions and integrating the REMS into electronic pharmacy management systems.